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H I G H L I G H T S
• Mechanical allodynia was alleviated after treatment with ATP-competitive mTOR inhibitors.
• The optical signals in the IC decreased after Torin1 and XL388 treatments.
• mTOR complex could be modulated for a more effective treatment of intractable pain.
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A B S T R A C T
In the pain matrix, the insular cortex (IC) is mainly involved in discriminative sensory and motivative emotion.
Abnormal signal transmission from injury site causes neuropathic pain, which generates enhanced synaptic
plasticity. The mammalian target of rapamycin (mTOR) complex is the key regulator of protein synthesis; it is
involved in the modulation of synaptic plasticity. To date, there has been no report on the changes in optical
signals in the IC under neuropathic condition after treatment with mTOR inhibitors, such as Torin1 and XL388.
Therefore, we aimed to determine the pain-relieving effect of mTOR inhibitors (Torin1 and XL388) and observe
the changes in optical signals in the IC after treatment. Mechanical threshold was measured in adult male
Sprague-Dawley rats after neuropathic surgery, and therapeutic effect of inhibitors was assessed on post-op-
erative day 7 following the microinjection of Torin1 or XL388 into the IC. Optical signals were acquired to
observe the neuronal activity of the IC in response to peripheral stimulation before and after treatment with
mTOR inhibitors. Consequently, the inhibitors showed the most effective alleviation 4 h after microinjection into
the IC. In optical imaging, peak amplitudes of optical signals and areas of activated regions were reduced after
treatment with Torin1 and XL388. However, there were no significant optical signal changes in the IC before and
after vehicle application. These findings suggested that Torin1 and XL388 are associated with the alleviation of
neuronal activity that is excessively manifested in the IC, and is assumed to diminish synaptic plasticity.
1. Introduction
Pain is considered as a signal from our body that helps detect
noxious stimuli or lesions. Acute pain can often be converted into
chronic pain due to various reasons, such as nerve or tissue injury,
inflammation, tumor growth, and viral infection (Kuner and Flor,
2016). These factors can also lead to neuropathic pain that induces
hyperalgesia, allodynia, and spontaneous pain, which are identified by
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abnormal sensory perception and stimulus-independent persistent pain
(Callin and Bennett, 2008; Jaggi and Singh, 2011). Although many
drugs are being developed to treat chronic pain, approximately 4–8% of
patients worldwide are still suffering from chronic pain as well as un-
expected side effects of the drugs (Li et al., 2016; Xu et al., 2012).
Recently, many studies have attempted to modulate the activation
of various regions of the brain for attenuating neuropathic pain (Cha
et al., 2017; Li et al., 2010; Metz et al., 2009). Regions of the brain that
participate in pain perception are involved in sensory-discriminative
properties or emotional aspects of pain (Apkarian et al., 2005; Basbaum
et al., 2009). Such regions of the brain—that is, the anterior cingulate
cortex (ACC), insular cortex (IC), primary somatosensory cortex (S1),
secondary somatosensory cortex (S2), and prefrontal cortex—constitute
the “pain matrix” (Garcia-Larrea and Peyron, 2013).
Among the regions constituting the pain matrix, the IC is mainly
associated with sensory discernment and emotion of pain (Lu et al.,
2016). Anterior part of the IC is cytoarchitectonically interconnected
with the limbic cortex, which regulates somatic nociceptive and visceral
inputs (Jasmin et al., 2004; Lutz et al., 2013). This morphological
evidence indicates that rostral part of the IC is identified in sensory
discernment and emotional processing of nociception (Lu et al., 2016).
Furthermore, when a lesion occurs in the rostral anterior IC, pain-like
behavior is significantly diminished (Coffeen et al., 2011). Human brain
imaging studies showed an increased neuronal activity in the IC after
high-intensity noxious stimulation (Baumgärtner et al., 2010; Craig
et al., 2000; Hess et al., 2007; Lorenz and Casey, 2005; Lorenz et al.,
2002).
The abnormal signals resulting from neuropathic pain alter synapses
and neurotransmitter properties, leading to long-term potentiation
(LTP) (Kuner, 2010; Kuner and Flor, 2016; Luo et al., 2014; Zhuo,
2008). LTP is affected by specific RNA-binding proteins and signal
transduction cascades, which modulate the initiation of mRNA trans-
lation (Klann et al., 2004; Pfeiffer and Huber, 2006). Major key reg-
ulators of mRNA translation are known as multiple extracellular sig-
naling-regulated kinases (ERK) and mammalian target of rapamycin
(mTOR) signaling pathways.
mTOR complex is a serine/threonine kinase, and it also affects cell
growth, cell proliferation, cell survival, and hormone regulation.
Rapamycin and rapalogs, which have been called the first-generation
mTOR inhibitors (Vilar et al., 2011), were developed for treating neu-
ropathic pain (Liu et al., 2009; Martelli et al., 2018); however, these
drugs were shown to be associated with side effects and limitations
related to alleviation of neuropathic pain (Guertin and Sabatini, 2009).
These limitations were expected due to the incomplete inhibition of
mTOR complex and the existence of feedback loop (Guertin and
Sabatini, 2009; Vilar et al., 2011). For complete inhibition of mTOR
complex, the second-generation mTOR inhibitors, called adenosine
triphosphate (ATP)-competitive inhibitors, were developed (Albert
et al., 2010). However, there is no electrophysiology- or optical ima-
ging-based evidence on the alleviation of neuropathic pain induced by
Torin1 and XL388.
To observe the changes in cortical excitability in the state of pain,
many researchers have performed optical imaging, as it could directly
measure the membrane potential changes and allow high-resolution
imaging of superficial brain structures (Cha et al., 2009; Chae et al.,
2010; Ferezou et al., 2009; Han et al., 2016; Kim et al., 2018). This
method helps reflect the membrane responses following changes in
neurons using a voltage-sensitive dye (VSD), which is sensitive to rapid
and linear membrane potential changes (Fehervari et al., 2015; Ferezou
et al., 2009; Fujita et al., 2010; Kobayashi et al., 2010).
Therefore, the purpose of the current study was to investigate the
correlation between the alleviative effect of mTOR inhibition on neu-
ropathic pain and the changes in pain-related neuronal activity patterns
in the IC. In this study, we elucidated the alleviative effect of ATP-
competitive mTOR inhibitors Torin1 and XL388 by comparing the
spatiotemporal patterns of cortical excitability using VSD imaging of
the IC in neuropathic rats.
2. Results
2.1. Development of mechanical allodynia induced by peripheral nerve
injury
We measured withdrawal threshold on the injured hind paw using
the electronic von Frey filament on PODs 1, 4, and 7 (Fig. 1). The
mechanical withdrawal threshold of nerve-injured group decreased
significantly from POD 1 to POD 7, and these values were significantly
lower than the corresponding values of sham-injured group
(p < 0.001, two-way ANOVA followed by Bonferroni’s post-hoc
multiple comparison test). However, the mechanical withdrawal
threshold had not shown any difference between groups before surgery
(p > 0.05).
2.2. Microinjection of Torin1 and XL388 into the IC reduces mechanical
allodynia
To investigate the effect of mTOR inhibition on neuropathic pain,
vehicle, Torin1, or XL388 were administered directly into the IC on
POD 7 by microinjection. Fig. 2A shows the locations of the injection
cannula tips in each group. The changes in mechanical withdrawal
threshold were examined 30 min and 1, 2, 4, 8, 12, and 24 h after
microinjection (Fig. 2B). The pain-relieving effect significantly in-
creased from 1 h to 4 h after Torin1 microinjection in NP group
(p < 0.05, n = 8, two-way ANOVA followed by Bonferroni’s post-hoc
multiple comparison test). Meanwhile, considerable pain alleviation
was observed only for 4 h after XL388 microinjection in NP group
(p < 0.01, n = 8). Both drugs significantly inhibited mechanical al-
lodynia 4 h after injection of each drug. The pain alleviative effect of
both drugs decreased 8 h after microinjection, and it reached the
threshold of the vehicle 24 h after microinjection. There were no sig-
nificant changes after vehicle microinjection in sham group during 24-h
period after microinjection (p > 0.05, n = 6). In vehicle-treated NP
group showed no changes in threshold during the 24-h period after
microinjection (p > 0.05, n = 8).
2.3. Correlation between electrical stimulation and optical responses in the
IC
To confirm the correlation of optical responses in the IC and
Fig. 1. Development of mechanical allodynia in sham-injured (Sham) and
nerve-injured (NP) rats. As neuropathic pain progressed, mechanical with-
drawal threshold changed significantly on post-operative days (PODs) 1, 4, and
7. Data are presented as means ± standard error of the mean (SEM).
***p < 0.001 vs. sham, as determined by two-way repeated-measures analysis
of variance (two-way ANOVA) followed by Bonferroni’s post-hoc multiple
comparison test.
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electrical stimulation of peripheral receptive field, Pearson’s correlation
coefficient was calculated. Since the correlation coefficient was higher
than 0.7, high correlation was confirmed between the peak amplitudes
of optical signals and intensity of electrical stimulation in vehicle-
treated NP group (p < 0.001, r = 0.8088, n = 8, one sample t-test,
Fig. 3A), Torin1-treated NP group (p < 0.001, r = 0.8478, n = 8,
Fig. 3C), and XL388-treated NP group (p < 0.001, r = 0.7816, n = 8,
Fig. 3E) before treatment. Before the application of mTOR inhibitors,
the high value of correlation coefficient indicated that there is a high
correlation between peak amplitudes and intensity of electrical stimu-
lation in all of the groups. After treatment with the vehicle in NP
groups, correlation coefficient remained high (p < 0.001, r = 0.7868,
n = 8, Fig. 3A). However, correlation coefficients were lower after
treatment with Torin1 (p > 0.05, r = 0.2710, n = 8, Fig. 3C) or
XL388 (p > 0.05, r = 0.1582, n = 8, Fig. 3E) in NP groups. In Fig. 3B,
D, and F, the region outlined with red indicates the activated area of the
IC before the application of vehicle or mTOR inhibitors, and the region
outlined with blue shows the activated areas after treatment with ve-
hicle or mTOR inhibitors. When electrical stimulation of the highest
intensity was applied to the nerve-injured hind paw, activation was
generally observed at granular insular cortex (GI), dysgranular insular
cortex (DI) in all groups before application of vehicle or mTOR in-
hibitiors (Fig. 3B, D, and F). After treatment with Torin1 and XL388, the
activation area of optical signals was noticeably decreased; however,
after treatment with the vehicle, broad activated areas still remained.
2.4. Changes in optical signals in the IC induced by Torin1 and XL388
Optical imaging using VSD demonstrates intuitive observation of
cortical activation. In this study, we observed the changes in cortical
activity of the IC in response to the electrical stimulation (0, 0.6, 1.25,
2.5, and 5 mA) applied to the nerve-injured paw of sham-surgery or
neuropathic rats. Fig. 4 compares the peak amplitudes of optical signals
in response to electrical stimulation before and after treatment with the
vehicle in sham group, vehicle, Torin1, or XL388 in NP group (Fig. 4A,
B, I, and J). The peak amplitude of cortical activity in the IC was
confirmed by maximal intensity value of optical signals (Fig. 4C, D, K,
and L). Each orange and blue line indicates averaged and filtered op-
tical intensity of the IC of the rats before and after application of vehicle
or mTOR inhibitors, respectively. Significant differences were not ob-
served between peak amplitudes before and after vehicle treatment in
sham group (p > 0.05, n = 5, two-way ANOVA, Fig. 4E). There were
Fig. 2. Illustration of stereotaxic implantation of
guide cannulae and the changes of mechanical
threshold following microinjection of vehicle,
Torin1, or XL388. (A) Histological identification of
the rostral anterior insular cortex (RAIC) with rat
atlas (Paxinos and Watson, 2006) using hematox-
ylin-eosin stain. The RAIC was located 1 mm ante-
riorly from the bregma (AP + 1). Subdivisions of the
IC are included in the black square box. Small circles
in the black square box indicate the locations of the
injection cannulae in each group. (B) The pain-re-
lieving effect following microinjection of vehicle,
Torin1, or XL388 into the IC on POD 7. Data are
presented as means ± SEM. *p < 0.05,
**p < 0.01 vs. vehicle, as determined by two-way
ANOVA followed by Bonferroni’s post-hoc multiple
comparison test.
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no significant differences between peak amplitudes before and after
vehicle treatment in neuropathic rats (p > 0.05, n = 8, two-way
ANOVA, Fig. 4F). In Torin1- and XL388-treated NP groups, the peak
amplitude of cortical activity increased proportionally with an increase
in the intensity of electrical stimulation before treatment. On the con-
trary, the peak amplitude of cortical activity was significantly reduced
after treatment with Torin1 and XL388 (p < 0.001, two-way ANOVA,
Fig. 4M and N). The peak amplitudes of optical activity at electrical
stimulation intensities of 1.25, 2.5, and 5 mA after the application of
Torin1 were significantly lower than those before treatment
(p < 0.001, n = 8, two-way ANOVA, Fig. 4M). The peak amplitudes of
optical signals in the IC at electrical stimulation intensities of 1.25, 2.5,
and 5 mA were significantly lower after treatment with XL388 than
they were before treatment (p < 0.001, n = 8, two-way ANOVA,
Fig. 4N). To compare the activated areas of the IC in response to
electrical stimulation, a circle with a radius of 20 pixels was set. Prior to
the application of vehicle, Torin1, or XL388 onto the IC in all groups,
the area of activated region increased with an increase in the intensity
of electrical stimulation of the hind paw (Fig. 4G, H, O, and P). After the
application of vehicle in sham and NP group, no significant changes in
the areas of activated regions of the IC were observed (p > 0.05, two-
way ANOVA, Fig. 4G and H). However, the area of activated region of
the IC reduced significantly after Torin1 or XL388 treatment
(p < 0.05, two-way ANOVA, Fig. 4O and P). The peak amplitudes of
optical signals were restored 2 h after Torin1 or XL388 was washed
(Supplementary Fig. 1). Besides, the peak amplitudes of optical signals
and areas of activated regions in sham group were not shown sig-
nificant changes after the application of vehicle, Torin1 or XL388
(Supplementary Fig. 2). This was to confirm whether the alleviation
effect of Torin1 or XL388 was caused by neuronal toxicity. These results
indicated that Torin1 and XL388 do not induce neuronal toxicity.
2.5. Stripe analysis of optical signals in the IC induced by electrical
stimulation
To analyze the spatial and temporal patterns of optical signals in the
IC, a stripe analysis of optical activity was performed (Fig. 5). Analysis
of stripe images was suitable for observing temporal variations of op-
tical activity within a particular region in different directions. In Fig. 5,
spatiotemporal patterns of neural activity were obtained from the line
in the corresponding optical images on the left side. In temporal ana-
lysis, vehicle-treated NP group showed prolonged excitation signals
Fig. 3. Correlation of optical signals in the IC and intensity of electrical stimulation on the peripheral receptive field of the injured hind paw before and after
treatment with the vehicle, Torin1, or XL388 in NP groups. The peak amplitudes of optical signals before and after treatment with the vehicle (A), Torin1 (C), or
XL388 (E) are plotted against the intensity of electrical stimulation. Pearson’s correlation coefficients (R) and p values are provided on the top left side of each graph.
Intuitive images of the area activated by electrical stimulation through optical imaging before and after treatment with the vehicle (B), Torin1 (D), or XL388 (F).
***p < 0.001 indicates that the correlation coefficient is statistically significant.
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with wide areas of activation, regardless of vehicle application
(Fig. 5A). Before Torin1 or XL388 treatment in NP groups, the corre-
sponding groups also showed a similar trend. However, noticeable
changes were observed in the IC after Torin1 or XL388 treatment in
nerve-injured groups. The duration for which the excitation signals and
enlarged areas of activation were observed was diminished after
treatment with Torin1 and XL388 in NP groups (Fig. 5B and C).
Fig. 4. Comparison of peak amplitudes and acti-
vated areas before and after treatment with the ve-
hicle, Torin1, or XL388. Representative optical
images of the IC before and after treatment with the
vehicle in sham group (A), and vehicle (B), Torin1
(I), XL388 (J) in NP group. Representative optical
signals from the IC before and after treatment with
the vehicle in sham group (C), and vehicle (D),
Torin1 (K), XL388 (L) in NP group. Comparison of
peak amplitudes before and after treatment with the
vehicle in sham group (E), and vehicle (F), Torin1
(M), XL388 (N) in NP group. Comparison of acti-
vated areas before and after treatment with the ve-
hicle in sham group (G), and vehicle (H), Torin1 (O),
XL388 (P) in NP group. A region of interest (ROI) for
analyzing the area of activation was expressed using
a red circle (a radius of 20 pixels). Data are pre-
sented as means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001 vs. before application of vehicle or
mTOR inhibitors, as determined by two-way
ANOVA followed by Bonferroni’s post-hoc multiple
comparison test.
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3. Discussion
The present study showed the efficacy of mTOR inhibitors and re-
corded the optical signals in the IC after treatment with Torin1 or
XL388 under neuropathic condition by using VSD imaging. The me-
chanical withdrawal threshold was increased by microinjection of
mTOR inhibitors as shown by the results of behavioral test. The changes
in optical signals of the IC using VSD imaging were observed before and
after the application of Torin1 or XL388. Our findings suggested that
mTOR inhibitors, Torin1 and XL388, alleviated pain and inhibited op-
tical responses of the IC to peripheral stimulation in the animal model
of neuropathy.
3.1. Effect of Torin1 and XL388 on the IC
Neuropathic pain produces spontaneous and abnormal signals in the
nervous system. These signals affect the modification of synapses and
neurotransmitter properties; therefore, these changes induce synaptic
plasticity. In the development of synaptic plasticity, phosphorylated
eukaryotic translation initiation factor 4E (eIF4E), eukaryotic
translation initiation factor 4E-binding proteins (4EBPs), and ribosomal
protein p70 S6 kinase (p70S6K) are mainly involved in the initiation of
mRNA translation and protein synthesis (Banko et al., 2005; Klann and
Dever, 2004; Pfeiffer and Huber, 2006; Wells, 2006). The mTOR com-
plex has been suggested as an upstream effector that controls these
proteins (Klann et al., 2004; Pfeiffer and Huber, 2006). This mTOR
complex is known as serine/threonine kinase, and is classified into
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) based on
their functions and constituents (Hay and Sonenberg, 2004; Hoeffer and
Klann, 2010; Laplante and Sabatini, 2012; Zoncu et al., 2011). The
downstream effectors affected by mTORC1 and mTORC2 are different.
The downstream effectors of mTORC1 are 4EBP1 and p70S6K (Klann
et al., 2004; Pfeiffer and Huber, 2006), and those of mTORC2 are
protein kinase B (AKT) and protein kinase C α (PKCα) (Dos et al., 2004;
Lee, 2006).
Many studies have reported that the phosphorylation of mTOR
complex increased not only in the spinal cord but also in the brain after
nerve injury (Lutz et al., 2015; Wang et al., 2015; Zhang et al., 2013).
Our previous studies also reported that the changes in phosphorylation
of mTOR complex were observed in the IC and ACC after neuropathic
Fig. 5. Representative images of stripe analysis related to optical activity after electrical stimulation of the peripheral receptive field in the injured hind paw before
and after vehicle, Torin1, or XL388 treatment. Electrical stimulation of the peripheral receptive field in the injured hind paw was 5 mA in intensity. Stripe images
were acquired through optical imaging in vehicle- (A), Torin1- (B), and XL388-treated (C) NP groups. Spatiotemporal activity was acquired from 0 to 1890 ms.
Spatiotemporal patterns were obtained from the blue lines on left images. The arrow on the bottom of right picture (dotted lines) shows the time point when electrical
stimulation was applied to the injured hind paw.
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pain developed (Kwon et al., 2017; Um et al., 2018). These studies
indicate that mTOR complex is involved in protein synthesis for sy-
naptic plasticity, which leads to mechanical allodynia.
Our previous reports showed that the microinjection of rapamycin
into the IC and ACC alleviated the mechanical allodynia following
peripheral nerve injury (Kwon et al., 2017; Um et al., 2018). These
studies indicated that the alleviation of neuropathic pain is possible
through mTOR complex regulation. However, rapamycin is the first-
generation mTOR complex inhibitor that has been reported to in-
completely inhibit the feedback loop, in addition to showing side effects
after long-term use (Guertin and Sabatini, 2009; Lisi et al., 2015). To
overcome these limitations, the second-generation mTOR inhibitors
were developed. ATP-competitive mTOR inhibitors are among the
second-generation mTOR inhibitors; Torin1 and XL388 block both
mTORC1 and mTORC2 by targeting the ATP site of the kinase domain
of mTOR complex (Albert et al., 2010). ATP-competitive mTOR in-
hibitors are inhibiting the phosphorylation of downstream effectors of
mTORC1 and mTORC2, thereby consequently inhibiting function of
mTORC1 and mTORC2 (Albert et al., 2010). Besides, ATP-competitive
mTOR inhibitors do not require co-factors such as FK-binding protein
12 (FKBP12) to bind with mTOR complex (Albert et al., 2010; Martelli
et al., 2018). These mTOR inhibitors do not cause mutations in the
FKBP-rapamycin binding protein (FRB) domain; therefore, they would
lead to fewer side effects when taken over a long-term period (Martelli
et al., 2018). mTOR complex is included in the phosphatidyl inositol 3′
kinase-related kinases (PIKK) family by its structural similarity (Aylett
et al., 2016; Yang and Guan, 2007). There are many kinases in the PIKK
family that interact with each other’s activities. Especially, phosphoi-
nositide-dependent kinase-1 (PDK1), phosphoinositide 3-kinase (PI3K),
and AKT are factors that are known to affect mTOR complex phos-
phorylation (Obara et al., 2012). Torin1 and XL388 also exert an in-
hibitory effect over AKT, PDK1, and PI3K, which are included in the
PIKK family. Therefore, these features suggest that Torin1 and XL388
are selective and potent inhibitors of mTOR complex.
A previous study related to Torin1 reported evident motor impair-
ment and clinical indications of toxicity in high dose of Torin1 (Obara
et al., 2011). The concentration of Torin1 used in the present study did
not cause side effects related to motor function, and these results were
consistent with a previous study (Cheng et al., 2016). There have been
no report on the side effects of XL388 related to sedative or locomotory
side effects (Crino, 2016; Martelli et al., 2018). In our experiment, it
was necessary to verify the alleviation of neuropathic pain by the
second-generation mTOR inhibitors, Torin1 and XL388, that simulta-
neously block mTORC1 and mTORC2. After microinjection of Torin1 or
XL388 into the IC, behavioral test was performed to confirm the effi-
cacy. The most effective time was 4 h after microinjection of Torin1 and
XL388. Regarding the mechanical withdrawal threshold, Torin1- and
XL388-treated groups showed higher peak values compared to vehicle-
treated group. The alleviative effect of Torin1 or XL388 on neuropathic
pain did not appear immediately, and this result was similar to that
observed in our previous studies, in which the mTOR inhibitor, rapa-
mycin, was microinjected into the IC and ACC under neuropathic
condition (Kwon et al., 2017; Um et al., 2018). Therefore, the pain-
relieving effect was shown by using ATP-competitive mTOR inhibitors,
and these effects are assumed to be due to changes in downstream ef-
fectors that were identified in our previous studies (Kwon et al., 2017;
Um et al., 2018). These results were short-term effects by single mi-
croinjection of Torin1 or XL388 into the IC on POD 7, which would help
patients who suffer from neuropathic pain as it will have fewer side
effects when taken for a long-term period. Further studies are needed to
explore the sedative-related side effects caused by ATP-competitive
mTOR inhibitors in clinical cases.
3.2. Changes in neuronal activity after Torin1 and XL388 treatment
Following the behavioral test, identification of the changes in
spatiotemporal patterns of optical signals in the IC before and after
treatment with Torin1 or XL388 was necessary. Therefore, we per-
formed VSD imaging, which is one of the electrophysiological techni-
ques that records the membrane potential alterations to offer visual
validation of the activity of neuronal population (An et al., 2012). Our
previous study demonstrated that neuropathic rats showed more sen-
sitive optical responses to the electrical stimulation of peripheral re-
ceptive field than sham-injured rats did (Han et al., 2016). Besides,
neuropathic rats also showed highly activated signals in the IC and ACC
under neuropathic condition before rapamycin treatment (Kwon et al.,
2017; Um et al., 2018). Similarly, we observed that the peak amplitudes
increased and the activated areas widened with an increase in the in-
tensity of electrical stimulation of the hind paw before treatment with
the vehicle, Torin1, or XL388 in neuropathic rats. The peak amplitudes
of optical signals and activated areas were highly correlated with the
intensity of peripheral stimulation before treatment; however, the
correlation became lowered after treatment of Torin1 or XL388. Also, it
was shown that the peak amplitude of optical signals at 0 mA of elec-
trical intensity was not completely 0, regardless of the application of
before and after Torin1 or XL388. The reason for the noise of optical
signals is related to the respiration and heart rate of experimental an-
imals; besides, the noise of optical signals could be due to the noise
from connecting wires or the device itself in the external environment.
The inhibition of mTORC1 and mTORC2 is expected to alleviate
excessive neuronal activity in the IC resulting from neuropathic pain
induced by nerve injury. Additionally, we observed distinctive changes
in optical signals under neuropathic condition after Torin1 or XL388
treatment of the IC. In vehicle-treated group, there were no significant
changes in peak amplitudes and excitatory areas of cortical activity.
Unlike vehicle-treated group, Torin1- and XL388-treated groups
showed a decrease in the peak amplitudes and excitatory areas of
cortical activity in the IC after treatment. The decreased activation of
the IC indicates that nerve-injured rats perceived less pain after Torin1
or XL388 treatment. These results show that inhibition of both mTORC1
and mTORC2 alleviates neuropathic pain.
The roles of mTORC1 and mTORC2 in synaptic plasticity are dif-
ferent. It is known that mTORC1 is involved in mRNA translation and
mTORC2 is involved in cytoskeletal rearrangement, which generates
structure or junction of synapses (Kelleher et al., 2004; Oh and Jacinto,
2011; Pfeiffer and Huber, 2006). Differences in their roles are due to the
differences in downstream effectors of mTORC1 and mTORC2 (Dos
et al., 2004; Lee, 2006). Torin1 and XL388 are ATP-competitive mTOR
inhibitors, which simultaneously inhibit the phosphorylation of both
mTORC1 and mTORC2 (Guertin and Sabatini, 2009; Liu et al., 2010;
Takeuchi et al., 2013). Since our previous studies confirmed the
changes induced in downstream effectors of mTORC1 by rapamycin
(Kwon et al., 2017; Um et al., 2018), we suggest that the downstream
effectors of mTORC1 and mTORC2 leading to the development of sy-
naptic plasticity might be altered by Torin1 and XL388. Therefore, the
changed expression levels of downstream phosphorylated effectors af-
fected mRNA translation and cytoskeletal rearrangement for generating
synaptic plasticity. These results indicate that a pain-relieving effect is
shown when mRNA translation and cytoskeletal rearrangement are
suppressed together. Our study suggests that the inhibition of mTORC1
and mTORC2 effectively contribute to the improved alleviation of
neuropathic pain.
3.3. Visible evidence of neural plasticity on optical imaging
In this study, we spatiotemporally mapped the neuronal activity of
the IC. Our findings indicated that the activated areas were enlarged,
and that the signals lasted longer in neuropathic rats. Additionally, the
decline in neural activity was observed as a result of mTOR inhibition.
These findings showed that mTOR inhibition has a pain-relieving effect
on severe neuropathic symptoms, and that it alleviates the hyper-acti-
vated neuronal activities in the IC. Previous studies showed that the
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optical signals of the IC increased depending on the intensity of elec-
trical stimulation of peripheral receptive field in neuropathic rats (Cha
et al., 2009; Han et al., 2016). These studies indicated that enlarged
activated areas and long-lasting neural activities in the IC after elec-
trical stimulation could explain the increased depolarization of neurons
in the cortex of nerve-injured rats. Based on these studies, we assumed
that neuronal excitation in neuropathy could be explained by the mTOR
pathway, and needed to further explore molecular changes by inhibi-
tion of both mTORC1 and mTORC2 in neuropathic pain condition.
Although optical imaging detects direct changes in cortical activity,
it can only observe cortical signals in a limited window. Due to this
limitation, we could not analyze the interactions of other pain-related
areas with the IC, as well as the responses between deep brain regions
and the IC. Nociceptive signals from the peripheral nerve injury have
been known to be transmitted to the thalamus through spinothalamic
tract, and these signals can activate the thalamus and other regions,
such as the prefrontal cortex, S1, S2, motor cortex, and ACC (Gogolla,
2017; Jaggi and Singh, 2011; Zhuo, 2008). Although nociceptive sig-
nals from the peripheral nerves can be directly transported to the IC,
there were also indirect pathways that convey nociceptive signals to the
IC through other pain-related brain regions (Gogolla, 2017). Therefore,
the temporal kinetics of responses such as latency, duration, and time to
peak in the IC would be diversified. Further studies are needed to ex-
plore the pathways between the IC and cortical or subcortical areas.
In conclusion, we observed the alleviative effect of ATP-competitive
mTOR inhibitors on neuropathic pain. Mechanical allodynia induced by
nerve injury was relieved in neuropathic rats after microinjection of
Torin1 or XL388 into the IC. Optical imaging using VSD showed that
the peak amplitudes of optical signals and the size of activated areas in
the IC were reduced after treatments with Torin1 or XL388. Pain-re-
lieving effect was the result of inhibition of both mTORC1 and
mTORC2. Nevertheless, it is difficult to determine whether mTORC1 or
mTORC2 has a greater effect on the neuropathic pain mechanism.
4. Experimental procedures
4.1. Experimental animals
Male Sprague-Dawley rats (weight, 250–280 g; Harlan, Koatec,
Pyeongtaek, Korea) were used for this study. All procedures adhered to
the National Institutes of Health guidelines, and were approved by the
Institutional Animal Care and Use Committee of Yonsei University
Health System (permit no. 2017–0076). Rats were allowed to acclimate
for 7 days after arrival; three animals were housed per cage and ex-
posed to 12-h light/dark cycles. Food and water were provided ad li-
bitum. The number of rats used in the experiment were 11 in sham
group and 16 per vehicle, Torin1, and XL388 groups, respectively.
4.2. Neuropathic surgery and cannula implantation
Nerve injury was induced as previously described (Lee et al., 2000),
following the period of acclimation. Rats were placed in the induction
chamber for anesthesia. A mixture of 5% vaporized isoflurane and
oxygen (2 L/min) was supplied into the induction chamber, and rats
were pulled out when their whiskers became motionless. An anesthetic
mask was placed on the snouts of rats to supply the same anesthetic gas
during surgery. The left sciatic nerve and its branches were exposed by
making an incision in the skin and muscles right above them. Tibial and
sural nerves were tightly ligated using 5–0 black silk and sectioned,
whereas common peroneal nerve was left intact. All surgical procedures
were performed within 20 min per rat, and the rats in sham-injured
group were subjected to an identical surgery without nerve injury.
Under sodium pentobarbital (50 mg/kg, intraperitoneal injection [i.p.])
anesthesia, rats were placed into stereotaxic frame. Guide cannula was
positioned according to the location, and bilaterally implanted into the
rostral anterior IC (1.0 mm anterior to bregma,± 4.7 mm lateral from
the midline, 5.8 mm below the surface of the skull (Han et al., 2015;
Jung et al., 2016; Kwon et al., 2017; Wu et al., 2016)). Rats were al-
lowed to recover for 1 week after cannula implantation.
4.3. Mechanical allodynia test
Mechanical allodynia test was performed 1 day before neuropathic
surgery and on POD 1, 4, and 7. On POD 7, each rat was placed in a
squared acrylic cage with a metal mesh floor, and was allowed to ha-
bituate for 15 min. The test was performed using an electrical von Frey
filament (no. 38450; UGO Basile, Varese, Italy). Filament was placed
vertically on the skin surface of the medial side of left hind paw, and
force values were measured until the animal exhibited withdrawal or
licked the hind paw. The measurements were repeated seven times with
2- to 3-minute intervals. The collected data, excluding the maximum
and minimum values, were averaged. All tests were performed in a
double-blinded fashion. Behavioral test was conducted before and 0.5,
1, 2, 4, 8, 12, 24 h after microinjection of Torin1 (No. 4247, Tocris,
Bristol, England), XL388 (No. 4893, Tocris), or vehicle on POD 7.
Behavioral test was performed on POD 7 to inhibit the synaptic plas-
ticity that might induce mechanical allodynia due to synaptic plasticity
in the IC by directly infused Torin1 or XL388.
4.4. Microinjection of Torin1 and XL388 into the IC
In this study, we used two types of second-generation mTOR com-
plex inhibitors: Torin1 and XL388. These inhibitors were diluted in
0.06% DMSO in saline. Saline-based 0.06% DMSO was used as vehicle.
Behavioral tests to determine the dose-dependent effects of Torin1 and
XL388 were conducted to apply the appropriate concentration in the IC
(Supplementary Fig. 3 and Fig. 4). The most effective concentration was
400 nM for Torin1, and 500 nM for XL388. On POD 7, 0.5 μl of Torin1
(400 nM), XL388 (500 nM), or vehicle was directly infused into the IC
bilaterally using the injection cannula with Hamilton syringes and PE-
10 tubing. The inhibitor or vehicle was injected at the rate of 0.5 μl/
min, and subsequently, injection cannula was placed in position for an
additional 1 min to prevent reflux along the injection cannula.
4.5. Optical imaging of the IC
The rats were re-anesthetized using urethane (1.25 g/kg, i.p.) on
POD 7. Urethane is the appropriate anesthetic drug for optical imaging,
since deep and long anesthesia does not interfere with neural function.
Infusion of the appropriate amount of urethane does not significantly
affect neural activity (Devonshire et al., 2010). To prevent mucus se-
cretion, which is a side effect of urethane, atropine (5 mg/kg, i.p.) was
administered to rats. Dexamethasone sulfate (1 mg/kg, i.p.) was also
administered to prevent the brain from swelling. Heart rate was mon-
itored by electrocardiography, and body temperature was maintained
at 36 °C using a rectal probe and heating pad system (Homeothermic
Blanket Control Unit, Harvard Apparatus, Holliston, MA, USA). After all
of the injections were administered, we waited until the rats were an-
esthetized. Then, rats were placed on the custom-made stereotaxic
frame. To ensure easy access to the IC, which is anterolaterally located
in the brain, rats were placed in a lateral position (Supplementary
Fig. 5). To induce local anesthesia, lidocaine was injected into the skin
and muscle of rats. After incising the skin, the muscular layer—which
covers the skull—was removed, and the zygomatic arch was revealed. It
was necessary to remove the zygomatic arch using a bone cutter to pull
the 4–0 black silk over the jaw-bone. If bleeding was severe, hemostatic
compound (ViscoStat®, Ultradent Products, Inc, South Jordan, UT,
USA) was used to stop the bleeding. Craniectomy was performed with
extreme care, since the internal maxillary vein is located beside the
zygomatic arch and superficial temporal vein. After craniectomy, dura
mater was also removed carefully to avoid injuring the cortex. To
prevent drying and bleeding, saline-soaked cotton balls were placed on
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the cortex. Finally, the exposed region of the IC was stained using a VSD
(di-2-ANEPEQ, 50 μg/mL in saline, Molecular Proves, Eugene, OR,
USA) for 1 h and subsequently, rinsed with saline observantly (Fig. 6A).
The surface of the brain was captured via digital camera, and the
captured image was edited to match the optical images to provide
image of the actual imaging site (Fig. 6A). For electrical stimulation of
peripheral receptive field, a pair of stainless-steel electrodes was pe-
netrated into the injured hind paws where the electronic von Frey fi-
lament was placed during behavioral test. Stimulation was applied in
the form of square pulse (width: 0.1 ms, interstimulus interval: 5 s,
intensity: 0, 0.6, 1.25, 2.5, and 5.0 mA) using a stimulus isolation unit
(World Precision Instruments, Sarasota, FL, USA).
Optical imaging was performed as previously described (Cha et al.,
2009; Han et al., 2016). An optical microscope (Leica Microsystems
Ltd., Heerbrugg, Switzerland), equipped with a 1× objective and 1×
projection lens, was positioned on the upper side of recording site.
Neuronal signals were detected using an optical imaging system con-
sisting of a high-resolution CCD camera (Brainvision Inc., Tokyo,
Japan) equipped with a dichroic mirror with 510–550 nm excitation
filter and 590 nm absorption filter. A tungsten halogen lamp (150 W)
was used as the source of fluorescence. The imaging area was ap-
proximately 6.4 × 4.8 mm2, and consisted of 184 × 124 pixels
(Fig. 6B). Detailed explanations of optical imaging are provided in
Supplementary Fig. 5. Optical images were acquired before and after
the application of vehicle, Torin1, or XL388 directly to the exposed the
IC for 30 min. The concentration of 0.06% DMSO in saline for vehicle,
400 nM of Torin1, or 500 nM of XL388 was applied on cortical surface
in optical imaging. These were the same concentrations as those used in
the behavioral test. After optical imaging, rats were euthanized by an
overdose of urethane.
4.6. VSD imaging analysis
The change in fluorescence intensity was observed for 1890 ms
during each trial. Optical signals were acquired using an optical ima-
ging recording system (MICAM02, Brainvision Inc.) at a rate of 3.7 ms/
frame and averaged 20 times. Optical image acquisition was triggered
by electrocardiogram signals using a stimulus/non-stimulus subtraction
method. The ratio of intensity of fluorescence (ΔF) in each pixel relative
to the initial fluorescence intensity (F) was revealed as a fractional
change (ΔF/F) to normalize the value of each pixel. Amplitudes and
excited areas of optical signals were calculated using a spatial filter
(9 × 9 pixels). The artifacts resulting from vibration and brain move-
ments were removed using a spatial filter. Data were collected and
identified using BV Analyzer software (Brainvision Inc.). The fractional
changes in optical signals (i.e., optical intensity) and areas of activation
were quantified. Changes in optical intensity in the IC were identified as
a percentage of fractional change in fluorescence (%ΔF/F). Activated
areas were described as the number of activated pixels divided by the
total number of pixels, which was expressed as a percentage of ROI. ROI
was set at a radius of 20 pixels to analyze the activation area of optical
signals. All data on optical intensity and activated areas were analyzed
using BV Analyzer software (Brainvision Inc.).
4.7. Statistical analysis
Statistical analyses were performed using GraphPad Prism
(Graphpad Software, San Diego, CA, USA). All values are presented as
mean ± SEM. Differences in mechanical withdrawal thresholds ob-
served during the behavioral test were analyzed using two-way
ANOVA, followed by Bonferroni’s post-hoc multiple comparison test.
Pearson’s correlation coefficient was used to determine the correlation
between peak amplitudes of optical signals and intensity of electrical
stimulation in peripheral receptive field. The correlation coefficient was
compared to 0 by one sample t-test. Differences in intensities of optical
signals and areas of activation were analyzed using paired t-test. P
values less than 0.05 were considered statistically significant.
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